Skip to main content

Isis Sued by Tet Systems for Alleged Patent Infringement


Isis Pharmaceuticals this week was sued by Germany's Tet Systems for allegedly infringing two US patents related to controllable gene expression technology, according to court documents.

Tet's technology involves the use of tetracycline to turn on or off the expression of specific genes at specific times.

According to Tet's suit, Isis allegedly used a cell line, called HepAD38, that contains the entire hepatitis B virus genome under the control of tetracycline prior to the expiration of two patents covering the technology, namely US patent Nos. 5,464,758 and 6,914,124.

Isis did so without "a license or other consent," and included data derived from this use in two of its patent applications, Tet charged in its suit.

"Isis' infringement has been knowing and willful," Tet added.

The suit seeks a declaration of Isis' infringement and an undisclosed award of damages.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.